-
SB 431542: From Pathway Probe to Translational Strategy
2026-09-07
A mechanistic and strategic guide to using SB 431542 as a selective ALK5 inhibitor across cancer, immune, fibrosis, and emerging human neuronal models.
-
PD98059 for Reproducible MEK–ERK Assays
2026-09-07
This scenario-driven guide explains how PD98059, SKU A1663, can help researchers interpret variable viability, proliferation, and cytotoxicity results through controlled MEK–ERK pathway inhibition. It covers mechanism, solvent handling, protocol parameters, data interpretation, cross-domain limitations, and practical vendor-selection criteria.
-
SR 11302: AP-1 Inhibitor Assay Guide
2026-09-05
This scenario-based guide explains how SR 11302 (AP-1 transcription factor inhibitor), SKU A8185, can improve experimental reasoning in cell proliferation, viability, and cancer-mechanism assays. It covers formulation control, dose selection, macrophage-model interpretation, and practical supplier evaluation without overstating translational evidence.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-04
The reference study identifies an LMO2/LDB1 protein complex as a functional regulator of acute myeloid leukemia cell growth and survival, extending LMO2 biology beyond its established roles in hematopoiesis and T-cell leukemia. By combining perturbation experiments, protein-interaction analysis, transcriptomics, and chromatin profiling, the authors provide a mechanistic framework for studying this transcriptional axis while highlighting the need for validation in primary AML models.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-04
The reference preprint shows that selected kinase inhibitors can both block p38α catalytic activity and accelerate WIP1-mediated removal of the activation-loop phospho-threonine. Structural and biochemical data link this effect to an inhibitor-stabilized activation-loop conformation, suggesting a conformation-focused strategy for improving kinase-inhibitor specificity and durability.
-
TAK-715: Practical p38 MAPK Inhibition Workflows
2026-09-03
TAK-715 combines nanomolar p38α selectivity with a workflow-friendly profile for cytokine assays, signaling studies, and rheumatoid arthritis research. This guide distinguishes direct kinase blockade from possible effects on phosphatase-driven dephosphorylation so researchers can build more informative inflammation experiments.
-
c-Myc Tag Peptide: From Displacement to Systems Insight
2026-09-03
A mechanistic and translational guide to using c-Myc tag Peptide A6003 for antibody-competition studies, assay validation, and more disciplined interpretation of transcription-factor biology.
-
Vemurafenib (PLX4032) Research Workflows
2026-09-02
Build genotype-aware melanoma assays with Vemurafenib (PLX4032), from rapid MAPK pathway readouts to long-term resistance modeling. This practical guide combines dosing, controls, multi-omics translation, and troubleshooting for reproducible cancer biology research.
-
Rotenone Workflows for Mitochondrial Stress
2026-09-02
Build reproducible mitochondrial stress experiments with Rotenone, a mitochondrial Complex I inhibitor suited to dose-response, redox, apoptosis, autophagy, and neurodegeneration workflows. This guide connects practical cell-based assays with the TCAIM–OGDH proteostasis findings reported in Molecular Cell, helping researchers distinguish electron-transport disruption from downstream metabolic remodeling.
-
NSC 87877: From Shp2 Mechanism to Translation
2026-09-01
NSC 87877 is more than a biochemical Shp2 inhibitor: it is a mechanistic probe for separating catalytic phosphatase activity from adaptor assembly, EGF–Ras–Erk signaling, leukemic-cell responses, and SHP2-linked neuroinflammation. This article translates those capabilities into a disciplined workflow for cancer, pain, and stroke researchers while defining the limits of current evidence.
-
Prestained Protein Marker: Triple-Color Workflow
2026-09-01
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides visible size landmarks for SDS-PAGE, Western blot transfer monitoring, and compatible fluorescent membrane workflows. It is appropriate for approximate protein-size verification and process control, but it should not be treated as a quantitative transfer assay or definitive confirmation of protein identity.
-
(-)-Arctigenin in TAM–EV Breast Cancer Models
2026-08-31
(-)-Arctigenin offers a mechanistically testable way to examine inflammatory signaling in tumor-associated macrophage extracellular-vesicle models. This article connects its NF-κB and MEK1 activities with the miR-660–KLHL21–IKKβ axis while emphasizing assay controls, causal interpretation, and research limitations.
-
Tomivosertib in AML: MNK1/2 Inhibition and eIF4E
2026-08-31
The 2021 Oncotarget study shows that selective MNK1/2 inhibition with Tomivosertib suppresses eIF4E Ser209 phosphorylation, AML cell viability, and leukemic progenitor colony formation. It also reports synergistic anti-leukemic activity with venetoclax and uses mass spectrometry to investigate previously unrecognized MNK1/2-associated proteins, strengthening the mechanistic rationale for MNK-eIF4E pathway studies in AML.
-
Tiamulin Inhibits TNF-α in Psoriasis Models
2026-08-30
The reference study used phenotype-based high-throughput screening to identify tiamulin fumarate as a small-molecule inhibitor of TNF-α-associated inflammation. In HaCaT cells and an imiquimod-induced mouse model, the compound reduced NF-κB and MAPK pathway activity and improved psoriasis-like dermatitis, supporting further mechanistic and translational investigation rather than immediate clinical use.
-
Regorafenib Workflows for Cancer Biology
2026-08-29
Regorafenib (BAY 73-4506) supports integrated studies of kinase signaling, angiogenesis, tumor-cell invasion, and melanoma mechanism. This practical guide connects concentration planning, migration assays, pathway validation, and tumor xenograft models with troubleshooting strategies that help distinguish cytotoxicity from genuine antimetastatic activity.